Jaguar Animal Health (NASDAQ:JAGX) Downgraded to “Strong Sell” Rating by Wall Street Zen

Jaguar Animal Health (NASDAQ:JAGX) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Friday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.00.

Jaguar Animal Health Price Performance

JAGX traded up $0.03 during trading on Friday, hitting $0.76. The company’s stock had a trading volume of 1,250,363 shares, compared to its average volume of 10,580,762. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08. The stock has a market capitalization of $2.86 million, a price-to-earnings ratio of -0.02 and a beta of -0.42. The firm’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.74. Jaguar Animal Health has a 12 month low of $0.64 and a 12 month high of $25.75.

Jaguar Animal Health (NASDAQ:JAGX) last announced its earnings results on Friday, November 14th. The biotechnology company reported ($6.28) EPS for the quarter, missing the consensus estimate of ($5.08) by ($1.20). Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 341.90%.The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $3.73 million. Sell-side analysts forecast that Jaguar Animal Health will post -0.8 earnings per share for the current fiscal year.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.